GWLL — Goldenwell Biotech Income Statement
0.000.00%
Last trade - 00:00- $297.00m
- $297.02m
- $0.00m
- 39
- 23
- 44
- 25
Annual income statement for Goldenwell Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.016 | 0.048 | 0.002 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0.008 | 0.025 | 0.001 | 0 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 0.006 | 0.134 | 1.03 | 0.118 | 0.123 |
| Operating Profit | -0.006 | -0.118 | -0.985 | -0.116 | -0.123 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.006 | -0.117 | -0.985 | -0.117 | -0.132 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.006 | -0.117 | -0.985 | -0.117 | -0.132 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.006 | -0.117 | -0.985 | -0.117 | -0.132 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.006 | -0.117 | -0.985 | -0.117 | -0.132 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0 | -0.001 | -0.01 | -0.001 | -0.001 |